caplacizumab-yhdp

Drug Overview

Caplacizumab-yhdp is a pioneering medication in the specialized field of hematology, designed to treat a rare, acute, and life-threatening blood clotting disorder. As an Anti-vWF Nanobody, this medication acts as a highly advanced Biologic and precise Targeted Therapy to stop the formation of dangerous micro-clots in the bloodstream.

For patients experiencing the sudden, terrifying onset of Acquired Thrombotic Thrombocytopenic Purpura (aTTP), the immediate clinical goal is to halt the destruction of blood cells and prevent catastrophic organ damage. Caplacizumab-yhdp serves as an essential bridge, working alongside traditional therapies to rapidly stabilize blood flow, protect vital organs, and dramatically improve survival rates during the most critical phases of the disease.

• Generic Name: caplacizumab-yhdp
• US Brand Names: Cablivi
• Drug Category: Hematology
• Drug Class: Anti-vWF Nanobody (von Willebrand Factor-Directed Antibody Fragment)
• Route of Administration: Intravenous (IV) injection and Subcutaneous (SC) injection
• FDA Approval Status: FDA-approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with therapeutic plasma exchange and immunosuppressive therapy.

What Is It and How Does It Work? (Mechanism of Action)

To understand how caplacizumab-yhdp works, we must first look at the condition it treats. In a healthy body, a protein called von Willebrand factor (vWF) circulates in the blood. When a blood vessel is injured, vWF acts like a sticky net to catch platelets and form a clot to stop the bleeding. A specific enzyme called ADAMTS13 acts like a pair of microscopic scissors, cutting these vWF nets so they do not get too large and cause unnecessary clots.

In patients with acquired Thrombotic Thrombocytopenic Purpura (aTTP), the body’s immune system mistakenly attacks and disables the ADAMTS13 “scissors.” Without this enzyme, ultra-large vWF strings remain in the bloodstream, uncontrollably catching platelets and forming hundreds of tiny clots inside the smallest blood vessels. This blocks blood flow to critical organs, such as the brain, heart, and kidneys. It also consumes the body’s supply of platelets, paradoxically leading to a high risk of dangerous internal bleeding elsewhere.

Caplacizumab-yhdp works as a highly precise Targeted Therapy. It is a “nanobody”—a miniature antibody designed to seek out and bind strictly to the A1 domain of the von Willebrand factor. By attaching itself directly to this specific part of the vWF protein, the drug physically blocks platelets from sticking to the vWF strings. While it does not fix the underlying lack of the ADAMTS13 enzyme (which is why patients still need plasma exchange and immunosuppressants), it instantly stops the dangerous micro-clots from forming. This protects the organs from ischemia (lack of oxygen) and allows the patient’s circulating platelet count to recover safely.

FDA-Approved Clinical Indications

Primary Indication

Caplacizumab-yhdp is specifically indicated for the treatment of adult patients experiencing an episode of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). It is used strictly in combination with daily therapeutic plasma exchange (PLEX) and Immunotherapy or immunosuppressive therapy (such as corticosteroids or rituximab). By utilizing this Biologic alongside plasma exchange, hematologists can achieve a much faster recovery of the patient’s platelet levels and significantly reduce the risk of the disease flaring up again during the critical recovery period.

Other Approved & Off-Label Uses

Because this drug is highly specialized to target the von Willebrand factor, its uses are carefully restricted.

• Approved: Adult aTTP episodes.
• Off-Label Uses: While not formally approved, it is occasionally investigated in clinical settings for other severe immune-mediated thrombotic microangiopathies (disorders where tiny clots form in small blood vessels) that show a strong von Willebrand factor dependence. Such use is strictly experimental and requires heavy hematological supervision.

Dosage and Administration Protocols

The administration of caplacizumab-yhdp is closely tied to the patient’s plasma exchange schedule and takes place in both inpatient and outpatient settings.

Important Adjustments:

• Treatment Extension: If the patient’s ADAMTS13 enzyme levels remain critically low or immune markers remain high after the initial 30 days, treatment may be extended for up to an additional 28 days to prevent an immediate relapse.
• Hepatic Insufficiency: No dose adjustment is needed for mild liver impairment, but the drug should be used with extreme caution in patients with severe hepatic impairment due to an increased baseline risk of bleeding.
• Missed Dose: If a dose is missed during the post-plasma exchange period, it can be administered if within 12 hours of the scheduled time. If more than 12 hours have passed, the missed dose should be skipped to maintain the regular schedule.

Clinical Efficacy and Research Results

The approval and ongoing clinical guidelines for caplacizumab-yhdp are backed by robust clinical evidence, most notably the pivotal Phase 3 HERCULES trial, with ongoing real-world registry data confirming its efficacy through 2024-2026.

In clinical trials involving acute aTTP patients, adding this medication to standard plasma exchange and immunosuppression resulted in a significantly faster recovery of platelet counts. Specifically, patients receiving caplacizumab-yhdp were 1.5 times more likely to achieve a normal platelet count at any given time point compared to those on a placebo.

Furthermore, clinical data demonstrates that this therapy reduced the rate of disease exacerbations (flares) by over 60% and nearly eliminated aTTP-related deaths during the study period. It also significantly reduced the number of days patients required plasma exchange and shortened the duration of their intensive care unit (ICU) stays, drastically improving overall survival and recovery trajectories for this severe blood disorder.

Safety Profile and Side Effects

Black Box Warning

There is no FDA Black Box Warning for caplacizumab-yhdp.

Common side effects (>10%)

Because this medication intentionally prevents platelets from clotting, the most common adverse reactions are related to mild or moderate bleeding:

• Epistaxis (nosebleeds)
• Gingival bleeding (bleeding gums)
• Headache
• Fatigue
• Fever
• Urticaria (hives)

Serious adverse events

• Severe Hemorrhage: Major, potentially life-threatening bleeding events, including gastrointestinal bleeding, genitourinary bleeding, or intracranial hemorrhage (bleeding in the brain). The risk is highest in patients with a history of bleeding disorders or severe untreated high blood pressure.
• Hypersensitivity: Severe allergic reactions to the drug formulation.

Management Strategies

If a patient experiences severe or clinically significant bleeding while on this therapy, the medication must be withheld immediately. Because the drug strongly binds to the von Willebrand factor, administering von Willebrand factor concentrate (along with other supportive bleeding management measures, such as red blood cell transfusions or surgical hemostasis) may be required by the medical team to rapidly reverse the anti-clotting effects.

Research Areas

Ongoing hematological research is exploring the broader applications of nanobody technology in blood disorders. Clinical trials are currently investigating the long-term outcomes of aTTP patients treated with caplacizumab-yhdp to determine if rapid micro-clot resolution prevents chronic, long-term kidney or neurological damage. Additionally, researchers are actively evaluating whether this drug, combined with advanced Immunotherapy to clear ADAMTS13 inhibitors, can eventually allow for “PLEX-free” (plasma exchange-free) treatment regimens, which would drastically reduce the physical burden and complication risks of hospital stays for patients.

Disclaimer: While the PEX-FREE trial and research into long-term organ preservation are highly promising and backed by early clinical data, Therapeutic Plasma Exchange (PLEX) remains the global professional standard of care for acute aTTP as of April 2026. Transitioning to a PLEX-free model is currently limited to specific clinical trials and has not yet been adopted into universal practice guidelines.

Patient Management and Practical Recommendations

Pre-treatment Tests

Before starting therapy, a hematology team will establish a clinical baseline:

• Complete Blood Count (CBC): To monitor platelet counts and hemoglobin levels daily.
• ADAMTS13 Activity: A crucial blood test to confirm the diagnosis of aTTP and monitor disease recovery.
• Coagulation Studies: PT/INR, aPTT, and vWF antigen levels to assess baseline bleeding risk.
• Organ Function: Liver and kidney panels to assess any micro-clot damage that has already occurred.

Precautions during treatment

• Bleeding Vigilance: Medical teams must monitor the patient constantly for signs of internal bleeding, such as sudden confusion, severe headaches, dark tarry stools, or blood in the urine.
• Transfusion Triggers: Platelet transfusions are generally avoided in active aTTP because they can “feed” the micro-clots. However, if life-threatening hemorrhage occurs, standard transfusion and reversal protocols are strictly utilized.
• Discontinuation for Surgery: The medication should be interrupted at least 7 days prior to elective surgery or dental procedures to prevent uncontrolled bleeding.

“Do’s and Don’ts” List

• DO report any unusual bleeding, including heavy menstrual bleeding, persistent nosebleeds, or sudden unexplained bruising, to your doctor immediately.
• DO carry a medical alert card stating that you are taking an Anti-vWF medication.
• DO use a soft-bristled toothbrush and an electric razor to minimize the risk of cuts and gum bleeding.
• DON’T take over-the-counter NSAIDs (like ibuprofen, aspirin, or naproxen) without your hematologist’s explicit permission, as these further increase bleeding risks.
• DON’T engage in high-impact or contact sports while receiving this treatment and for at least a month afterward.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. The information in this guide is intended to help patients and providers understand the general use of caplacizumab-yhdp. Because Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is a complex medical emergency, all treatment decisions, dosage adjustments, and safety protocols must be strictly guided by a licensed specialist hematologist or attending physician.